Axonics (AXNX) Stock Price, News & Analysis

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Key Stats

• Today's Range: $70.98 to $70.98
• 50-Day Range: $69.66 to $70.98
• 52-Week Range: $67.38 to $71.05
• Volume: N/A
• Average Volume: 427,857 shs
• Market Capitalization: $3.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

AXNX Stock Analysis - Frequently Asked Questions

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) posted its quarterly earnings data on Thursday, November, 7th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. Axonics's revenue was up 24.8% compared to the same quarter last year.

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axonics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), NVIDIA (NVDA), TotalEnergies (TTE) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 7/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AXNX
• CIK: 1603756
• Web: www.axonics.com
• Phone: (949) 396-6322
• Fax: 949-396-6321
• Employees: 610
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 322.64
• P/E Growth: N/A
• Net Income: -$6.09 million
• Net Margins: -1.31%
• Pretax Margin: -0.70%
• Return on Equity: 0.36%
• Return on Assets: 0.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.16
• Quick Ratio: 6.40

Sales & Book Value

• Annual Sales: $366.38 million
• Price / Sales: 9.90
• Cash Flow: $0.13 per share
• Price / Cash Flow: 561.96
• Book Value: $12.59 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 51,110,000
• Free Float: 50,163,000
• Market Cap: $3.63 billion
• Optionable: Optionable
• Beta: 0.82